1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Informed Consent Form
   Response - Clinical Study Report
   Response -  Analytic Code
   
   
3. Who will be able to view these files?
   Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [docd5321@gmail.com].
   


6. For how long will this data be available start date provided 15-01-2028 and end date provided 15-01-2031?
   Response - Beginning 9 months and ending 36 months following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

The use of pegfilgrastim, a long-acting granulocyte-colony stimulating factor (G-CSF), has improved the management of chemotherapy-induced neutropenia. Neutropenia is one of the most common adverse effects of chemotherapy and can result in serious infections, hospitalisations, and dose reductions, which can compromise the effectiveness of chemotherapy. Pegylated filgrastim is a modified form of G-CSF that has a longer half-life and can reduce the frequency of dosing compared to non-pegylated formulations.

Several studies have compared the efficacy and safety of low-dose 3 mg pegfilgrastim (Peg-3) with the standard 6 mg dose (Peg-6) in patients receiving chemotherapy. This was based on the comparable pharmacokinetics of 60mcg/kg and 100mcg/kg doses. Overall, these studies have shown that Peg-3 is non-inferior to Peg-6 in terms of its ability to reduce the duration and severity of chemotherapy-induced neutropenia, the incidence of febrile neutropenia, and the need for dose reductions or delays.

One randomised, double-blind, phase III study compared the efficacy and safety of Peg-3 with Peg-6 in patients with breast cancer receiving docetaxel and cyclophosphamide chemotherapy. The study found no significant difference between the two groups in terms of the incidence of febrile neutropenia, the duration of severe neutropenia, or the need for dose reduction or delays. Other studies have reported similar findings, showing no significant differences in efficacy between Peg-3 and Peg-6 in various chemotherapy regimens, including those for colorectal cancer, lung cancer, and urothelial carcinoma. In terms of safety, both Peg-3 and Peg-6 have been well-tolerated, with similar rates of adverse events reported in clinical trials.

In conclusion, the use of low-dose 3 mg pegfilgrastim is a viable and effective option for the prevention of chemotherapy-induced neutropenia. The available literature suggests that Peg-3 is non-inferior to Peg-6 in terms of its ability to reduce the duration and severity of neutropenia, the incidence of febrile neutropenia, and the need for dose reductions or delays. As such, Peg-3 may offer some advantages over Peg-6, including reduced cost and potentially lower risk of adverse events. Further studies are needed to confirm these findings and determine the optimal dosing strategy for pegfilgrastim in different patient populations. The use of low-dose Peg GCSF has not been well studied thoroughly in India.. In this study, we are comparing 3 mg Peg GCSF vs 6 mg in carcinoma breast patients receiving AC/EC in neoadjuvant/adjuvant setting.